Synonym
Citalopram oxalate; (+/-)-Citalopram oxalate; UNII-B5RDX2419X
IUPAC/Chemical Name
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, ethanedioate (1:1)
InChi Key
KTGRHKOEFSJQNS-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H21FN2O.C2H2O4/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;3-1(4)2(5)6/h4-9,12H,3,10-11,14H2,1-2H3;(H,3,4)(H,5,6)
SMILES Code
N#CC1=CC2=C(C(C3=CC=C(F)C=C3)(CCCN(C)C)OC2)C=C1.O=C(O)C(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
414.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: de Diego HL, Bond AD, Dancer RJ. Formation of solid solutions between racemic and enantiomeric citalopram oxalate. Chirality. 2011 May;23(5):408-16. doi: 10.1002/chir.20943. Epub 2011 Apr 6. PMID: 21472783.
2: Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. PMID: 12387707.
3: Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018 Feb;22(2):1167-1178. doi: 10.1111/jcmm.13372. Epub 2017 Nov 3. PMID: 29105282; PMCID: PMC5783874.
4: Xu JH, Jiang P. Efficacy of escitalopram oxalate for patients with post- stroke depression. Medicine (Baltimore). 2018 Apr;97(14):e0219. doi: 10.1097/MD.0000000000010219. PMID: 29620632; PMCID: PMC5902280.
5: Blumenthal SR, Castro VM, Clements CC, Rosenfield HR, Murphy SN, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Smoller JW, Perlis RH. An electronic health records study of long-term weight gain following antidepressant use. JAMA Psychiatry. 2014 Aug;71(8):889-96. doi: 10.1001/jamapsychiatry.2014.414. PMID: 24898363.
6: Valipour R, Yilmaz MB, Valipour E. Study of DNA-Binding Activity and Antibacterial Effect of Escitalopram Oxalate, an Extensively Prescribed Antidepressant. Drug Res (Stuttg). 2019 Oct;69(10):545-550. doi: 10.1055/a-0809-5044. Epub 2019 Jan 7. PMID: 30616249.
7: Badulla WFS, Atkoşar Z, Arli G, Şener E. Application of LC-ESI-MS/MS Method for Analysis of Escitalopram Oxalate in Human Urine and Pharmaceutical Dosage Forms. J Chromatogr Sci. 2020 Jan 23;58(2):91-97. doi: 10.1093/chromsci/bmz073. PMID: 31681957.
8: Khanna S, Chirinos RE, Venna S. Escitalopram oxalate (Lexapro)-induced acneiform eruption. J Am Acad Dermatol. 2012 Dec;67(6):e261-3. doi: 10.1016/j.jaad.2012.03.032. PMID: 23158626.
9: Ma L, Lu ZN, Hu P, Yao CJ. Neuroprotective effect of escitalopram oxalate in rats with chronic hypoperfusion. J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):514-518. doi: 10.1007/s11596-015-1462-x. Epub 2015 Jul 31. PMID: 26223919.
10: Shen Y, Zhao Q, Yu Y, Tan Y, Zhang H, Xu X, Wang Z, Li Y, Hu J, Zhong J, Li H. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. J Affect Disord. 2019 Oct 1;257:143-149. doi: 10.1016/j.jad.2019.07.023. Epub 2019 Jul 5. PMID: 31301615.
